MOA Life Plus Co. Ltd.
Research MOA Life Plus Co. Ltd. (142760.KQ) on Bullrun: market cap KRW 10.96B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker142760.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 10.96B
- Financial periodQ2 2026
- RevenueKRW 2.34B
- Net income-KRW 7.91B
- Free cash flow-KRW 977.95M
- Gross margin21.8%
Valuation Snapshot
latest market cap is KRW 10.96B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 10.96B | n/a | n/a | n/a |
Dividend history
About MOA Life Plus Co. Ltd.
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MOA Life Plus Co. Ltd.'s market cap?
MOA Life Plus Co. Ltd.'s market capitalization is KRW 10.96B.
What does MOA Life Plus Co. Ltd. do?
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics.